InsiderTrades.com logo
917 Trades… Zero Losses?
From Insiders Exposed   |   Ad
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Go here to see how you can start accessing these opportunities today
Craig A. Collard net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Craig Collard Biography and Net Worth

Director of Sierra Oncology
Mr. Craig Collard is currently the CEO of Veloxis Pharmaceutics, Inc., a transplant focused pharmaceutical company, now a subsidiary of Asahi Kasei after its acquisition of Veloxis for $1.3 billion in 2020. Prior to this, he served as the CEO and Chairman of Cornerstone Therapeutics, Inc., a pharmaceutical company he founded in 2004, until February 2014 when the company was purchased by Chiesi Pharmaceuticals, Inc. Before founding Cornerstone, Mr. Collard served as President and CEO of Carolina Pharmaceuticals, Inc., a pharmaceutical company he founded in May 2003. From 1998 to 2003, Mr. Collard served in various commercial roles at Verum Pharmaceuticals, Inc., and DJ Pharma, Inc. Mr. Collard is a member of the Board of Directors of Veloxis, Opiant Pharmaceutics, Inc. and TerrAscend Corporation. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia.

What is Craig A. Collard's net worth?

The estimated net worth of Craig A. Collard is at least $10.26 million as of November 16th, 2023. Mr. Collard owns 186,496 shares of Sierra Oncology stock worth more than $10,255,415 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Collard may own. Learn More about Craig A. Collard's net worth.

How do I contact Craig A. Collard?

The corporate mailing address for Mr. Collard and other Sierra Oncology executives is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. Sierra Oncology can also be reached via phone at (604) 558-6536 and via email at [email protected]. Learn More on Craig A. Collard's contact information.

Has Craig A. Collard been buying or selling shares of Sierra Oncology?

Craig A. Collard has not been actively trading shares of Sierra Oncology in the last ninety days. Most recently, on Tuesday, November 23rd, Craig A. Collard bought 5,601 shares of Sierra Oncology stock. The stock was acquired at an average cost of $22.95 per share, with a total value of $128,542.95. Learn More on Craig A. Collard's trading history.

Who are Sierra Oncology's active insiders?

Sierra Oncology's insider roster includes Gaurav Aggarwal (Director), Craig Collard (Director), Stephen Dilly (CEO), Mary Thomson (General Counsel), and William Turner (Insider). Learn More on Sierra Oncology's active insiders.

Craig A. Collard Insider Trading History at Sierra Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2021Buy5,601$22.95$128,542.95View SEC Filing Icon  
See Full Table

Craig A. Collard Buying and Selling Activity at Sierra Oncology

This chart shows Craig A Collard's buying and selling at Sierra Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sierra Oncology Company Overview

Sierra Oncology logo
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $54.99
Low: $54.99
High: $54.99

50 Day Range

MA: $54.93
Low: $54.73
High: $54.99

2 Week Range

Now: $54.99
Low: $14.91
High: $55.19

Volume

N/A

Average Volume

931,731 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03
917 Trades… Zero Losses?
From Insiders Exposed   |   Ad
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Go here to see how you can start accessing these opportunities today